Panacea Biotec Limited (NSE:PANACEABIO)
India · Delayed Price · Currency is INR 407.65
+6.25 (1.56%)
Aug 4, 2025, 2:30 PM IST
bluebird bio Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
| 5,591 | 5,592 | 4,599 | 6,612 | 6,248 | Upgrade | |
Revenue Growth (YoY) | -0.01% | 21.57% | -30.44% | 5.83% | 14.84% | Upgrade |
Cost of Revenue | 1,995 | 2,301 | 2,527 | 2,622 | 2,046 | Upgrade |
Gross Profit | 3,596 | 3,290 | 2,073 | 3,990 | 4,202 | Upgrade |
Selling, General & Admin | 1,731 | 1,643 | 1,517 | 2,050 | 1,774 | Upgrade |
Other Operating Expenses | 2,124 | 1,695 | 1,192 | 1,987 | 1,544 | Upgrade |
Operating Expenses | 4,203 | 3,705 | 3,100 | 4,474 | 3,774 | Upgrade |
Operating Income | -607.2 | -414.69 | -1,027 | -484.18 | 427.33 | Upgrade |
Interest Expense | -38.8 | -26.73 | -38.03 | -1,798 | -1,847 | Upgrade |
Interest & Investment Income | - | 83.81 | 120.62 | 33.94 | 32.68 | Upgrade |
Earnings From Equity Investments | - | - | - | - | 0.77 | Upgrade |
Currency Exchange Gain (Loss) | - | 36.23 | 20.77 | 5.8 | -6.88 | Upgrade |
Other Non Operating Income (Expenses) | 206.6 | -9.08 | -6.34 | -10.02 | -6.45 | Upgrade |
EBT Excluding Unusual Items | -439.4 | -330.46 | -930.37 | -2,253 | -1,399 | Upgrade |
Gain (Loss) on Sale of Investments | - | 33.67 | 14.47 | 0.01 | - | Upgrade |
Gain (Loss) on Sale of Assets | - | -2.64 | 52.93 | 0.07 | -0.38 | Upgrade |
Asset Writedown | - | -46.14 | -29.94 | -15.75 | -42.63 | Upgrade |
Other Unusual Items | 359.9 | 360.34 | 1,021 | 16,762 | - | Upgrade |
Pretax Income | -79.5 | 14.77 | 128.05 | 14,494 | -1,442 | Upgrade |
Income Tax Expense | 7.7 | 29.82 | 465.5 | 3,710 | 19.57 | Upgrade |
Earnings From Continuing Operations | -87.2 | -15.05 | -337.45 | 10,783 | -1,462 | Upgrade |
Earnings From Discontinued Operations | - | - | - | - | -14.55 | Upgrade |
Net Income to Company | -87.2 | -15.05 | -337.45 | 10,783 | -1,477 | Upgrade |
Minority Interest in Earnings | 3.5 | 3.32 | 5.08 | -0.19 | -0.38 | Upgrade |
Net Income | -83.7 | -11.73 | -332.37 | 10,783 | -1,477 | Upgrade |
Net Income to Common | -83.7 | -11.73 | -332.37 | 10,783 | -1,477 | Upgrade |
Shares Outstanding (Basic) | 61 | 61 | 61 | 61 | 61 | Upgrade |
Shares Outstanding (Diluted) | 61 | 61 | 61 | 61 | 61 | Upgrade |
Shares Change (YoY) | -0.25% | - | - | - | - | Upgrade |
EPS (Basic) | -1.37 | -0.19 | -5.43 | 176.05 | -24.11 | Upgrade |
EPS (Diluted) | -1.37 | -0.19 | -5.43 | 176.05 | -24.11 | Upgrade |
Free Cash Flow | -776.8 | -778.18 | -4,634 | -1,210 | 848.87 | Upgrade |
Free Cash Flow Per Share | -12.71 | -12.71 | -75.66 | -19.75 | 13.86 | Upgrade |
Gross Margin | 64.31% | 58.85% | 45.07% | 60.35% | 67.25% | Upgrade |
Operating Margin | -10.86% | -7.42% | -22.34% | -7.32% | 6.84% | Upgrade |
Profit Margin | -1.50% | -0.21% | -7.23% | 163.08% | -23.64% | Upgrade |
Free Cash Flow Margin | -13.89% | -13.92% | -100.75% | -18.29% | 13.59% | Upgrade |
EBITDA | -259.1 | -47.58 | -636.16 | -56.28 | 872.65 | Upgrade |
EBITDA Margin | -4.63% | -0.85% | -13.83% | -0.85% | 13.97% | Upgrade |
D&A For EBITDA | 348.1 | 367.11 | 391.23 | 427.9 | 445.32 | Upgrade |
EBIT | -607.2 | -414.69 | -1,027 | -484.18 | 427.33 | Upgrade |
EBIT Margin | -10.86% | -7.42% | -22.34% | -7.32% | 6.84% | Upgrade |
Effective Tax Rate | - | 201.90% | 363.53% | 25.60% | - | Upgrade |
Revenue as Reported | 5,798 | 5,850 | 5,116 | 6,722 | 6,348 | Upgrade |
Advertising Expenses | - | 113.04 | 218.21 | 220.05 | 183.74 | Upgrade |
Updated Feb 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.